# First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

> **NCT01215136** · PHASE2 · TERMINATED · sponsor: **Matthew Galsky** · enrollment: 36 (actual)

## Conditions studied

- Transitional Cell Carcinoma
- Bladder Carcinoma
- Urothelial Carcinoma

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Everolimus
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01215136
- **Lead sponsor:** Matthew Galsky
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2017-04-24
- **Final completion:** 2018-04-24
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2023-11-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215136, "First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01215136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*